Tumour growth and metastasis are highly dependent on the formation of new blood vessels, a process termed tumour angiogenesis. As conventional treatment strategies face challenges such as tumour resistance and recurrence, interventions targeting angiogenesis have…
In a significant advancement for multiple myeloma treatment, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio™ (elranatamab-bcmm) on August 14, 2023. This bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, developed…
Among the latest advances in the pharmaceutical field, Golidocitinib Capsules, a new generation of JAK1 inhibitors, is attracting a lot of attention. The drug’s development background, clinical trial results, and market outlook all indicate its…
On 9 August 2023, the US Food and Drug Administration (FDA) announced the accelerated approval of TALVEY™ (generic: talquetamab-tgvs) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). These patients will…
Introduction Cidofovir is an antiviral medication primarily used to treat cytomegalovirus (CMV) retinitis in patients with AIDS. This guide provides an in-depth look at its uses, dosage, potential side effects, precautions, and other essential information…
Zevorcabtagene Autoleucel is a CAR-T cell therapy targeting B-cell maturation antigen (BCMA) by genetically engineering a patient’s own T cells to precisely recognize and kill multiple myeloma cells that express BCMA, a marker highly expressed…
In the ever-evolving field of oncology, the development of targeted therapies has revolutionized the way we approach cancer treatment. One such advancement is the emergence of Welireg (belzutifan), a novel therapeutic agent that has shown promise…
Pretomanid 200 mg tablets are a novel nitroimidazooxazine-based anti-tuberculosis drug that kills Mycobacterium tuberculosis by inhibiting mycobacterial cell wall synthesis. Its unique dual mechanism of action makes it an excellent candidate for drug-resistant TB. Based…
In October 2022, the U.S. Food and Drug Administration (FDA) granted accelerated TECVAYLI™ (teclistamab-cqyv) FDA approval, a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. For the treatment of adult patients with relapsed or refractory…
UCB has recently announced that its innovative therapy, Bimzelx (generic name: bimekizumab-bkzx), has received approval from the U.S. Food and Drug Administration (FDA) for multiple new indications, solidifying its role in treating various immune-mediated inflammatory…
In the world of immunology and asthma management, Benralizumab Injection has emerged as a game-changer for patients struggling with severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). This monoclonal antibody, developed by AstraZeneca in…
On October 11, 2024, Junshi Biosciences announced that its self-developed recombinant humanized anti-PCSK9 monoclonal antibody injection, Ongericimab (brand name: JUNSHID®). Has been approved by the National Medical Products Administration (NMPA) for the treatment of adult…
